SKYE BIOSCIENCE INC (SKYE) Fundamental Analysis & Valuation

NASDAQ:SKYE • US83086J2006

0.7213 USD
-0.08 (-9.7%)
At close: Mar 11, 2026
0.6911 USD
-0.03 (-4.19%)
After Hours: 3/11/2026, 8:25:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This SKYE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, SKYE scores 2 out of 10 in our fundamental rating. SKYE was compared to 519 industry peers in the Biotechnology industry. While SKYE seems to be doing ok healthwise, there are quite some concerns on its profitability. SKYE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. SKYE Profitability Analysis

1.1 Basic Checks

  • SKYE had negative earnings in the past year.
  • SKYE had a negative operating cash flow in the past year.
  • In the past 5 years SKYE always reported negative net income.
  • In the past 5 years SKYE always reported negative operating cash flow.
SKYE Yearly Net Income VS EBIT VS OCF VS FCFSKYE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -123.97%, SKYE is doing worse than 79.96% of the companies in the same industry.
  • With a Return On Equity value of -156.02%, SKYE is not doing good in the industry: 63.97% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -123.97%
ROE -156.02%
ROIC N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SKYE Yearly ROA, ROE, ROICSKYE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

  • SKYE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SKYE Yearly Profit, Operating, Gross MarginsSKYE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SKYE Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for SKYE has been increased compared to 1 year ago.
  • SKYE has more shares outstanding than it did 5 years ago.
  • SKYE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SKYE Yearly Shares OutstandingSKYE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SKYE Yearly Total Debt VS Total AssetsSKYE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • Based on the Altman-Z score of -7.56, we must say that SKYE is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -7.56, SKYE is doing worse than 68.40% of the companies in the same industry.
  • There is no outstanding debt for SKYE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.56
ROIC/WACCN/A
WACCN/A
SKYE Yearly LT Debt VS Equity VS FCFSKYE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 4.77 indicates that SKYE has no problem at all paying its short term obligations.
  • SKYE has a Current ratio (4.77) which is comparable to the rest of the industry.
  • SKYE has a Quick Ratio of 4.77. This indicates that SKYE is financially healthy and has no problem in meeting its short term obligations.
  • SKYE's Quick ratio of 4.77 is in line compared to the rest of the industry. SKYE outperforms 56.65% of its industry peers.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.77
SKYE Yearly Current Assets VS Current LiabilitesSKYE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. SKYE Growth Analysis

3.1 Past

  • The earnings per share for SKYE have decreased strongly by -218.02% in the last year.
EPS 1Y (TTM)-218.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, SKYE will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.84% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-96.84%
EPS Next 2Y-23.01%
EPS Next 3Y-17.24%
EPS Next 5Y-19.84%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SKYE Yearly Revenue VS EstimatesSKYE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 2033 100M 200M 300M
SKYE Yearly EPS VS EstimatesSKYE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. SKYE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SKYE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SKYE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SKYE Price Earnings VS Forward Price EarningsSKYE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SKYE Per share dataSKYE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A cheap valuation may be justified as SKYE's earnings are expected to decrease with -17.24% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.01%
EPS Next 3Y-17.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SKYE Dividend Analysis

5.1 Amount

  • SKYE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SKYE Fundamentals: All Metrics, Ratios and Statistics

SKYE BIOSCIENCE INC

NASDAQ:SKYE (3/11/2026, 8:25:17 PM)

After market: 0.6911 -0.03 (-4.19%)

0.7213

-0.08 (-9.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-18
Inst Owners50.42%
Inst Owner Change-17.71%
Ins Owners1.52%
Ins Owner Change0%
Market Cap23.12M
Revenue(TTM)N/A
Net Income(TTM)-51.23M
Analysts81.43
Price Target8.89 (1132.5%)
Short Float %2.92%
Short Ratio2.23
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-370.59%
Min EPS beat(2)-746.82%
Max EPS beat(2)5.65%
EPS beat(4)3
Avg EPS beat(4)-179.91%
Min EPS beat(4)-746.82%
Max EPS beat(4)17.2%
EPS beat(8)4
Avg EPS beat(8)-91.51%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.23%
EPS NY rev (3m)0.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-3.53
EYN/A
EPS(NY)-1.09
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS0
BVpS1.02
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -123.97%
ROE -156.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.54%
ROA(5y)-179.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.77
Altman-Z -7.56
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)207.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-220%
EPS Next Y-96.84%
EPS Next 2Y-23.01%
EPS Next 3Y-17.24%
EPS Next 5Y-19.84%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-97.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-183.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-176.83%
OCF growth 3YN/A
OCF growth 5YN/A

SKYE BIOSCIENCE INC / SKYE FAQ

What is the fundamental rating for SKYE stock?

ChartMill assigns a fundamental rating of 2 / 10 to SKYE.


Can you provide the valuation status for SKYE BIOSCIENCE INC?

ChartMill assigns a valuation rating of 0 / 10 to SKYE BIOSCIENCE INC (SKYE). This can be considered as Overvalued.


Can you provide the profitability details for SKYE BIOSCIENCE INC?

SKYE BIOSCIENCE INC (SKYE) has a profitability rating of 0 / 10.


Can you provide the financial health for SKYE stock?

The financial health rating of SKYE BIOSCIENCE INC (SKYE) is 6 / 10.